PAMINE FORTE Drug Patent Profile
✉ Email this page to a colleague
When do Pamine Forte patents expire, and when can generic versions of Pamine Forte launch?
Pamine Forte is a drug marketed by Fougera Pharms and is included in one NDA.
The generic ingredient in PAMINE FORTE is methscopolamine bromide. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the methscopolamine bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pamine Forte
A generic version of PAMINE FORTE was approved as methscopolamine bromide by BRECKENRIDGE PHARM on December 6th, 2011.
Summary for PAMINE FORTE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 49 |
Patent Applications: | 931 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PAMINE FORTE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for PAMINE FORTE
US Patents and Regulatory Information for PAMINE FORTE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fougera Pharms | PAMINE FORTE | methscopolamine bromide | TABLET;ORAL | 008848-002 | Mar 25, 2003 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |